320 related articles for article (PubMed ID: 10507778)
1. Immunochemical analysis of cathepsin B in lung tumours: an independent prognostic factor for squamous cell carcinoma patients.
Werle B; Lötterle H; Schanzenbächer U; Lah TT; Kalman E; Kayser K; Bülzebruck H; Schirren J; Krasovec M; Kos J; Spiess E
Br J Cancer; 1999 Oct; 81(3):510-9. PubMed ID: 10507778
[TBL] [Abstract][Full Text] [Related]
2. Cathepsin B, plasminogenactivator-inhibitor (PAI-1) and plasminogenactivator-receptor (uPAR) are prognostic factors for patients with non-small cell lung cancer.
Werle B; Kotzsch M; Lah TT; Kos J; Gabrijelcic-Geiger D; Spiess E; Schirren J; Ebert W; Fiehn W; Luther T; Magdolen V; Schmitt M; Harbeck N
Anticancer Res; 2004; 24(6):4147-61. PubMed ID: 15736466
[TBL] [Abstract][Full Text] [Related]
3. Cysteine proteinase cathepsin H in tumours and sera of lung cancer patients: relation to prognosis and cigarette smoking.
Schweiger A; Staib A; Werle B; Krasovec M; Lah TT; Ebert W; Turk V; Kos J
Br J Cancer; 2000 Feb; 82(4):782-8. PubMed ID: 10732746
[TBL] [Abstract][Full Text] [Related]
4. Cathepsin B in infiltrated lymph nodes is of prognostic significance for patients with nonsmall cell lung carcinoma.
Werle B; Kraft C; Lah TT; Kos J; Schanzenbächer U; Kayser K; Ebert W; Spiess E
Cancer; 2000 Dec; 89(11):2282-91. PubMed ID: 11147599
[TBL] [Abstract][Full Text] [Related]
5. Cathepsin B fraction active at physiological pH of 7.5 is of prognostic significance in squamous cell carcinoma of human lung.
Werle B; Jülke B; Lah T; Spiess E; Ebert W
Br J Cancer; 1997; 75(8):1137-43. PubMed ID: 9099961
[TBL] [Abstract][Full Text] [Related]
6. The expression of cyclins D1 and E in predicting short-term survival in squamous cell carcinoma of the lung.
Anton RC; Coffey DM; Gondo MM; Stephenson MA; Brown RW; Cagle PT
Mod Pathol; 2000 Nov; 13(11):1167-72. PubMed ID: 11106072
[TBL] [Abstract][Full Text] [Related]
7. Changes in plasminogen activator inhibitor-1 levels in non-small cell lung cancer.
Pavey SJ; Marsh NA; Ray MJ; Butler D; Dare AJ; Hawson GA
Boll Soc Ital Biol Sper; 1996; 72(11-12):331-40. PubMed ID: 9178585
[TBL] [Abstract][Full Text] [Related]
8. Laminin and cathepsin B as prognostic factors in stage I non-small cell lung cancer: are they useful?
Mori M; Kohli A; Baker SP; Savas L; Fraire AE
Mod Pathol; 1997 Jun; 10(6):572-7. PubMed ID: 9195574
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of the tumor suppressor gene maspin in non-small cell lung cancer.
Hirai K; Koizumi K; Haraguchi S; Hirata T; Mikami I; Fukushima M; Yamagishi S; Kawashima T; Okada D; Shimizu K; Kawamoto M
Ann Thorac Surg; 2005 Jan; 79(1):248-53. PubMed ID: 15620951
[TBL] [Abstract][Full Text] [Related]
10. Relevance of proliferative and pro-apoptotic factors in non-small-cell lung cancer for patient survival.
Volm M; Koomägi R
Br J Cancer; 2000 May; 82(10):1747-54. PubMed ID: 10817513
[TBL] [Abstract][Full Text] [Related]
11. Increased cathepsin B activity in human lung tumors.
Krepela E; Kasafírek E; Novák K; Viklický J
Neoplasma; 1990; 37(1):61-70. PubMed ID: 2320181
[TBL] [Abstract][Full Text] [Related]
12. Activity and tissue localization of cathepsin D in non small cell lung cancer.
Chyczewski L; Płoński A; Chyczewska E; Furman M; Ostrowska H; Nikliński J; Kozłowski M
Rocz Akad Med Bialymst; 1997; 42 Suppl 1():217-29. PubMed ID: 9337539
[TBL] [Abstract][Full Text] [Related]
13. Vascular endothelial growth factor, platelet-derived endothelial cell growth factor and angiogenesis in non-small-cell lung cancer.
O'Byrne KJ; Koukourakis MI; Giatromanolaki A; Cox G; Turley H; Steward WP; Gatter K; Harris AL
Br J Cancer; 2000 Apr; 82(8):1427-32. PubMed ID: 10780522
[TBL] [Abstract][Full Text] [Related]
14. Tumour CEA as predictor of better outcome in squamous cell carcinoma of the lung.
Veronesi G; Pelosi G; Sonzogni A; Leon ME; D'Aiuto M; Gasparri R; De Braud F; De Pas T; Sandri M; Spaggiari L
Lung Cancer; 2005 May; 48(2):233-40. PubMed ID: 15829323
[TBL] [Abstract][Full Text] [Related]
15. Telomerase activity as a prognostic indicator in stage I non-small cell lung cancer.
Marchetti A; Bertacca G; Buttitta F; Chella A; Quattrocolo G; Angeletti CA; Bevilacqua G
Clin Cancer Res; 1999 Aug; 5(8):2077-81. PubMed ID: 10473089
[TBL] [Abstract][Full Text] [Related]
16. Cystatins in non-small cell lung cancer: tissue levels, localization and relation to prognosis.
Werle B; Schanzenbächer U; Lah TT; Ebert E; Jülke B; Ebert W; Fiehn W; Kayser K; Spiess E; Abrahamson M; Kos J
Oncol Rep; 2006 Oct; 16(4):647-55. PubMed ID: 16969475
[TBL] [Abstract][Full Text] [Related]
17. Tissue MMP-2 and MMP-9 [corrected] are better prognostic factors than serum MMP-2/TIMP-2--complex or TIMP-1 [corrected] in stage [corrected] I-III lung carcinoma.
Hoikkala S; Pääkkö P; Soini Y; Mäkitaro R; Kinnula V; Turpeenniemi-Hujanen T
Cancer Lett; 2006 May; 236(1):125-32. PubMed ID: 15982804
[TBL] [Abstract][Full Text] [Related]
18. Nuclear p53 overexpression is an independent prognostic parameter in node-negative non-small cell lung carcinoma.
Dalquen P; Sauter G; Torhorst J; Schultheiss E; Jordan P; Lehmann S; Solèr M; Stulz P; Mihatsch MJ; Gudat F
J Pathol; 1996 Jan; 178(1):53-8. PubMed ID: 8778317
[TBL] [Abstract][Full Text] [Related]
19. p16 protein expression is associated with a poor prognosis in squamous cell carcinoma of the lung.
Huang CI; Taki T; Higashiyama M; Kohno N; Miyake M
Br J Cancer; 2000 Jan; 82(2):374-80. PubMed ID: 10646891
[TBL] [Abstract][Full Text] [Related]
20. Adenomatous polyposis coli gene promoter hypermethylation in non-small cell lung cancer is associated with survival.
Brabender J; Usadel H; Danenberg KD; Metzger R; Schneider PM; Lord RV; Wickramasinghe K; Lum CE; Park J; Salonga D; Singer J; Sidransky D; Hölscher AH; Meltzer SJ; Danenberg PV
Oncogene; 2001 Jun; 20(27):3528-32. PubMed ID: 11429699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
